Loading...
1482. Microbiological Analysis from a Phase II Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
BACKGROUND: Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits bacterial replication and has in vitro activity against key pathogens, including drug-resistant strains, associated with a range of infections. METHODS: This phase IIa single-center...
Na minha lista:
Udgivet i: | Open Forum Infect Dis |
---|---|
Main Authors: | , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Oxford University Press
2019
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808788/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1346 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|